NGS引导下的奥希替尼耐药肺腺癌1例报道

Diagnosis and treatment of a case of osimertinib resistant lung adenocarcinoma guided by NGS

目的探讨下一代测序(NGS)引导下奥希替尼耐药后的肺腺癌患者的诊治,在临床工作中探索个体化全程管理方案。方法回顾性分析1例经过多次动态NGS检测的奥希替尼耐药肺腺癌患者的临床资料,对目前奥希替尼耐药的肺腺癌研究进展进行文献复习。结果经过多次动态基因检测,先后发现MET扩增、EGFR C797S突变,针对性选用相应靶向药治疗后取得较好疗效。结论靶向治疗患者前应进行动态基因检测,个体化指导下一步治疗。

Objective To explore the diagnosis and treatment of osimertinib-resistant lung adenocarcinoma patients guided by next-generation sequencing(NGS),and to explore individualized whole-process management programs in clinical work.Methods The clinical data of a patient with osimertinib-resistant lung adenocarcinoma who had undergone multiple dynamic NGS tests were retrospectively analyzed,and the current research progress of osimertinib-resistant lung adenocarcinoma was reviewed.Results After several times of dynamic gene tests,MET amplification and EGFR C797S mutation were successively found,and the corresponding targeted drugs were selected for treatment and achieved a good curative effect.Conclusion Dynamic genetic testing should be undergo before targeted therapy for the next step of treatment.